Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension
Condition(s):Pulmonary Hypertension; Sickle Cell DiseaseLast Updated:April 19, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Pulmonary Hypertension; Sickle Cell DiseaseLast Updated:April 19, 2021Completed
Condition(s):Sickle Cell DiseaseLast Updated:October 26, 2023Recruiting
Condition(s):Alpha and Beta Thalassemia; Sickle Cell Disease; Malaria; Human PhysiologyLast Updated:March 12, 2024Recruiting
Condition(s):Sickle Cell DiseaseLast Updated:September 14, 2023Withdrawn
Condition(s):Pain; Sickle Cell DiseaseLast Updated:September 24, 2018Completed
Condition(s):Sickle-Cell Disease Nos With CrisisLast Updated:February 8, 2023Recruiting
Condition(s):Anemia, Sickle Cell; Cerebral Embolism and Thrombosis; Cerebrovascular Disorders; Hematologic Diseases; HemoglobinopathiesLast Updated:December 23, 2015Completed
Condition(s):Sickle Cell DiseaseLast Updated:May 3, 2023Completed
Condition(s):Skin Ulcers; Sickle Cell AnemiaLast Updated:March 31, 2015Completed
Condition(s):Sickle Cell Disease; PainLast Updated:July 2, 2017Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.